Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

MediWound (MDWD) EBITDA Margin (2016 - 2025)

MediWound has reported EBITDA Margin over the past 12 years, most recently at 384.84% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 31799.0% year-over-year to 384.84%; the TTM value through Dec 2025 reached 18.23%, up 11260.0%, while the annual FY2025 figure was 140.93%, 850.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 384.84% at MediWound, down from 49.01% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 344.06% in Q2 2025 and troughed at 384.84% in Q4 2025.
  • A 5-year average of 66.54% and a median of 73.93% in 2021 define the central range for EBITDA Margin.
  • On a YoY basis, EBITDA Margin climbed as much as 18724bps in 2025 and fell as far as -31799bps in 2025.
  • Year by year, EBITDA Margin stood at 75.71% in 2021, then grew by 15bps to 64.36% in 2022, then skyrocketed by 49bps to 32.86% in 2023, then tumbled by -103bps to 66.85% in 2024, then tumbled by -476bps to 384.84% in 2025.
  • Business Quant data shows EBITDA Margin for MDWD at 384.84% in Q4 2025, 49.01% in Q3 2025, and 344.06% in Q2 2025.